R
Robert Kozarski
Researcher at AstraZeneca
Publications - 2
Citations - 262
Robert Kozarski is an academic researcher from AstraZeneca. The author has contributed to research in topics: Olaparib & Homologous recombination. The author has an hindex of 2, co-authored 2 publications receiving 166 citations.
Papers
More filters
Journal ArticleDOI
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel W. Clarke,Paweł Wiechno,Boris Alekseev,Nuria Sala,Robert H. Jones,Ivo Kocak,Vincenzo Emanuele Chiuri,Jacek Jassem,Aude Flechon,Charles H. Redfern,C. Goessl,Joseph Burgents,Robert Kozarski,Darren Hodgson,Maria Learoyd,Fred Saad +15 more
TL;DR: Olaparib in combination with abiraterone provided clinical efficacy benefit for patients with metastatic castration-resistant prostate cancer and preclinical data suggest synergy between olaparIB and androgen pathway inhibitors.
Journal ArticleDOI
Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
Noel W. Clarke,Paweł Wiechno,Boris Alekseev,Núria Sala,R. Jones,Ivo Kocák,Vincenzo Emanuele Chiuri,Jacek Jassem,Aude Flechon,Charles H. Redfern,C. Goessl,Joseph Burgents,Robert Kozarski,Darren Hodgson,Fred Saad +14 more
TL;DR: This data indicates that mCRPC pts with a homologous recombination repair mutation (HRRm) previously showed improved response to the PARP inhibitor olaparib (Lynparza) as monotherapy vs pts without a HRRm (...)